iOnctura SA, a clinical stage biopharmaceutical company, announced on Wednesday that it has named Dr Joanna Horobin as its new non-executive chair to the company's board with immediate effect.

Dr Horobin is a drug developer and biotech leader with more than 35 years of experience in the pharmaceutical and biotech sector in Europe and the US. She has held multiple C-suite roles in biotech companies in the US, most recently as the chief medical officer at Idera Pharmaceuticals Inc and was also the CEO of Syndax Pharmaceuticals. She joined Beecham Pharmaceuticals in 1982. She moved to cancer drug development while at Rhone Poulenc Rorer (now Sanofi), in France and US. She headed a joint venture between Rhone Poulenc and Chugai to develop and launch Chugai's gCSF product Granocyte in Europe and, as VP Oncology, launched Rhone Poulenc Rorer as a major player in oncology with the global launch of Taxotere. She serves as a non-executive director on the boards of Nordic Nanovector ASA, Liquidia Technologies Inc and privately held Kymera Therapeutics Inc.

Dr Horobin said, 'iOnctura has a very exciting pipeline of molecules targeting oncology and fibrosis for application in pioneering therapies. I am very much looking forward to working closely with the team and my board colleagues as we shape the next chapter in iOnctura's evolution and future success.'